TCM
AEGR

Tekla Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Tekla Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-206,000
Closed -$2.8M – 168
2015
Q3 		$2.8M Hold
206,000
– – 0.1% 130
2015
Q2 		$3.91M Hold
206,000
– – 0.14% 93
2015
Q1 		$5.39M Buy
+206,000
New +$5.24M 0.21% 79
2014
Q3 		– Sell
-20
Closed -$1K – 109
2014
Q2 		$1K Sell
20
-72,500
-100% -$2.7M ﹤0.01% 64
2014
Q1 		$3.35M Buy
+72,520
New +$4.25M 0.33% 50
2013
Q4 		– Sell
-11,880
Closed -$1.02M – 64
2013
Q3 		$1.02M Buy
+11,880
New +$1.01M 0.11% 61

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Tekla Capital Management's AEGR Position: Q4 2015 in Review

Tekla Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 206,000 shares — an estimated $2.8M sold.

Tekla Capital Management first reported a position in AEGR in Q3 2013 and held it in 6 quarters. The position peaked at $5.39M in Q1 2015. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • Tekla Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Tekla Capital Management sold 206,000 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $2.8M.
  • Tekla Capital Management first reported a position in Aegerion Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Tekla Capital Management's Aegerion Pharmaceuticals position peaked at $5.39M in Q1 2015.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on Tekla Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.